Department of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland.
Swiss Med Wkly. 2009 Nov 28;139(47-48):678-84. doi: 10.4414/smw.2009.12765.
Insulin resistance is the main clinical and pathogenetic feature of the metabolic syndrome, one of the major health problems worldwide. Chronic liver diseases may induce insulin resistance. The hepatic manifestation of the metabolic syndrome is nonalcoholic fatty liver disease. Insulin promotes the storage of energy in the fed state by stimulation of glycogen synthesis, lipogenesis, suppression of gluconeogenesis and VLDL formation. Epidemiological studies have shown that chronic hepatitis C induces insulin resistance. Insulin resistance in chronic hepatitis C is associated with progression of liver fibrosis, resistance to antiviral therapy and development of hepatocellular carcinoma. Here we review the major findings from epidemiological studies from 1994 to the present which have resulted in our current knowledge of insulin resistance in chronic hepatitis C. We further summarise the preliminary pathogenetic models that explain the development of hepatitis C virus-induced insulin resistance. Finally, we draw conclusions for the clinical management of these patients.
胰岛素抵抗是代谢综合征的主要临床和发病特征,也是全球主要的健康问题之一。慢性肝脏疾病可能会导致胰岛素抵抗。代谢综合征的肝脏表现是非酒精性脂肪性肝病。胰岛素通过刺激糖原合成、脂肪生成、抑制糖异生和 VLDL 形成来促进进食状态下能量的储存。流行病学研究表明,慢性丙型肝炎会引起胰岛素抵抗。慢性丙型肝炎中的胰岛素抵抗与肝纤维化的进展、抗病毒治疗的耐药性以及肝细胞癌的发生有关。本文综述了自 1994 年以来的流行病学研究中的主要发现,这些发现使我们目前对慢性丙型肝炎中的胰岛素抵抗有了一定的认识。我们进一步总结了初步的发病机制模型,以解释丙型肝炎病毒引起的胰岛素抵抗的发展。最后,我们为这些患者的临床管理得出结论。